Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b
0% citation coverage
New Phase 2b data for Pfizer's berobenatide (formerly MET097) show robust and continuous weight loss with monthly dosing, reinforcing its potential as a differentiated obesity therapy. The results offer key insights for analysts and BD teams tracking the Pfizer weight loss drug name and the broader obesity pipeline.
Intelligence Snapshot
Executive Summary
Pfizer's berobenatide (formerly MET097) shows strong weight loss with monthly dosing in Phase 2b.
Key Insights
- No plateau was observed at week 28, suggesting sustained efficacy.
-
The drug was acquired from Metsera, which previously reported up to 14.1% weight loss…
The drug was acquired from Metsera, which previously reported up to 14.1% weight loss with a weekly regimen.
- Data support differentiation in the obesity market via less frequent dosing.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | high |
| Investment | medium |
Loading intelligence…
Quick Answer
Pfizer's berobenatide (formerly MET097) shows strong weight loss with monthly dosing in Phase 2b.
Key Questions
- What were the results of the Metsera trial?
- When will the Pfizer weight loss pill be available?
- What is the Pfizer weight loss drug name?
- How does MET097 weight loss compare to other GLP-1 drugs?
- What is the VESPER-3 trial?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for berobenatide.
Unlock full calendar →Pfizer pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Contents7 sections
Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b
New Phase 2b data for Pfizer's berobenatide (formerly MET097) show strong and continuous weight loss with monthly dosing, reinforcing its potential as a differentiated obesity therapy. The results offer key insights for analysts and BD teams tracking the Pfizer weight loss drug name and the broader obesity pipeline.
IntelligenceRegulatory Impact
FDA and EMA decisions frame this story. Regulatory relevance is medium for obesity, with berobenatide most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- Pfizer's berobenatide (formerly MET097) shows strong weight loss with monthly dosing in Phase 2b.
- No plateau was observed at week 28, suggesting sustained efficacy.
- The drug was acquired from Metsera, which previously reported up to 14.1% weight loss with a weekly regimen.
- Data support differentiation in the obesity market via less frequent dosing.
IntelligenceCompetitive Intelligence
Competitive pressure is high. Pfizer and Metsera reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.
The Development
On June 6, 2026, STAT reported detailed Phase 2b data for Pfizer's monthly obesity drug berobenatide, acquired from Metsera. The ultra-long-acting injectable GLP-1 RA demonstrated strong and continuous weight loss after switching to monthly dosing, with no plateau at week 28. This builds on Metsera's earlier Phase 2b results, which showed up to 14.1% weight loss with a weekly regimen. The data offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy, a key differentiator in a market dominated by weekly injections like semaglutide and tirzepatide.
IntelligenceMarket Signals
Commercial pull is medium and investment relevance medium for obesity. Expect implications for pricing, access, and launch sequencing.
Implications for Pharma Teams
For analysts and BD teams, these data strengthen the case for berobenatide as a differentiated monthly option in the obesity market. The lack of plateau at week 28 suggests potential for sustained efficacy, which could improve patient adherence in a therapeutic area where persistence is notoriously poor. Upcoming milestones include the VESPER-3 trial and MET-097i Phase 3 readouts, which will inform regulatory filing timing and market access strategy. Competitive benchmarking against weekly GLP-1 RAs is now critical, as the monthly dosing schedule could allow Pfizer to capture a segment of patients who are averse to weekly injections. The company's broader obesity pipeline, including its oral candidates, will also be watched closely as the market evolves.
Frequently Asked Questions
What were the results of the Metsera trial?
Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a Phase 2b trial of the weekly regimen of berobenatide (then called MET097).
When will the Pfizer weight loss pill be available?
Pfizer has not yet announced a timeline for regulatory filing or launch of berobenatide. The drug is still in Phase 2b development, with Phase 3 trials expected to begin in 2027 at the earliest, pending data from the VESPER-3 and MET-097i trials.
What is the Pfizer weight loss drug name?
Pfizer's monthly obesity drug is called berobenatide. It was previously known as MET097 when it was owned by Metsera. The drug is an ultra-long-acting injectable GLP-1 receptor agonist.
How does MET097 weight loss compare to other GLP-1 drugs?
In Metsera's Phase 2b trial, MET097 achieved up to 14.1% weight loss with weekly dosing. The new Phase 2b data from Pfizer show continued weight loss with monthly dosing, with no plateau at week 28. This compares favorably to weekly GLP-1 RAs like semaglutide and tirzepatide, though head-to-head trials have not been conducted.
What is the VESPER-3 trial?
The VESPER-3 trial is an upcoming clinical study for berobenatide. It will evaluate the drug's efficacy and safety in a larger patient population, likely serving as a key Phase 3 readout that will support regulatory filing. Details are expected to be posted on ClinicalTrials.gov once recruitment begins.
What is the MET-097i Phase 3 trial?
MET-097i Phase 3 is another pivotal trial for berobenatide. It is expected to test the monthly dosing regimen in a broader cohort, including patients with obesity-related comorbidities. The trial design and endpoints will be critical for market access and payer discussions.
IntelligenceStrategic Takeaways
Pfizer's berobenatide (formerly MET097) shows strong weight loss with monthly dosing in Phase 2b. No plateau was observed at week 28, suggesting sustained efficacy. The drug was acquired from Metsera, which previously reported up to 14.1% weight loss with a weekly regimen.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About obesity
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow berobenatide developments
FDA obesity alerts and berobenatide pipeline updates, every Monday.
- Sources analyzed
- 1
- Evidence strength
- 58/100
- Last verified
- Jun 6, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Limited source quality · grounded in cited primary and secondary sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Continue Your Research
Industry Reports & Whitepapers
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…